Synapse - Komal Jhaveri

Results (204)

Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update

Guidelines

Andre, F.; Ismaila, N.; Allison, K. H.; Barlow, W. E.; Collyar, D. E.; Damodaran, S.; Henry, N. L.; Jhaveri, K.; Kalinsky, K.; Kuderer, N. M.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

The oncogenic PI3K-induced transcriptomic landscape reveals key functions in splicing and gene expression regulation

Journal Article

Ladewig, E.; Michelini, F.; Jhaveri, K.; Castel, P.; Carmona, J.; Fairchild, L.; Zuniga, A. G.; Arruabarrena-Aristorena, A.; Cocco, E.; Blawski, R.; more...
Cancer Research (2022)

Fulltext@MSK | Save

Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: Feasibility of precision oncology biomarker detection

Journal Article

Cani, A. K.; Dolce, E. M.; Darga, E. P.; Hu, K.; Liu, C. J.; Pierce, J.; Bradbury, K.; Kilgour, E.; Aung, K.; Schiavon, G.; more...
Molecular Oncology (2022)

Fulltext@MSK | Save

Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment

Journal Article

Liu, D.; Weintraub, M. A.; Garcia, C.; Goncalves, M. D.; Sisk, A. E.; Casas, A.; Harding, J. J.; Harnicar, S.; Drilon, A.; Jhaveri, K.; more...
Cancer Medicine (2022)

Fulltext@MSK | Save

Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A phase 1b study

Journal Article

Tolaney, S. M.; Beeram, M.; Beck, J. T.; Conlin, A.; Dees, E. C.; Puhalla, S. L.; Rexer, B. N.; Burris, H. A. 3rd; Jhaveri, K.; Helsten, T.; more...
Frontiers in Oncology (2022)

Fulltext@MSK | Save

A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study

Meeting Abstract

Jhaveri, K. L.; Lim, E.; Hamilton, E. P.; Saura, C.; Meniawy, T.; Jeselsohn, R.; Beck, J. T.; Kaufman, P. A.; Sammons, S.; Banda, K.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC)

Meeting Abstract

Jhaveri, K. L.; Boni, V.; Sohn, J.; Villanueva-Vásquez, R.; Bardia, A.; Schmid, P.; Lim, E.; Patel, J. M.; Perez-Fidalgo, J. A.; Loi, S.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC)

Meeting Abstract

Moore, H. M.; Boni, V.; Bellet, M.; De Las Heras, B. B.; Cortés, M. G.; Oakman, C.; Schmid, P.; Trinh, X. B.; Wheatley, D.; Jhaveri, K. L.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors